Improvement of Lipid Metabolism and Ovalbumin-Induced Type I Allergy by Use of Soybean Milk Fermented by 16 Indigenous Lactic Acid Bacteria

Yuichi Nodake*, Ryoko Miura, Hirokazu Ryoya, Rina Momii, Satomi Toda, Ryuzo Sakakibara

Department of Biochemistry, Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo, Nagasaki, Japan

Email address: nodake@niu.ac.jp (Y. Nodake)

*Corresponding author

To cite this article: Yuichi Nodake, Ryoko Miura, Hirokazu Ryoya, Rina Momii, Satomi Toda, Ryuzo Sakakibara. Improvement of Lipid Metabolism and Ovalbumin-Induced Type I Allergy by Use of Soybean Milk Fermented by 16 Indigenous Lactic Acid Bacteria. Journal of Food and Nutrition Sciences. Vol. 4, No. 4, 2016, pp. 113-119. doi: 10.11648/j.jfns.20160404.17

Received: July 10, 2016; Accepted: July 18, 2016; Published: July 29, 2016

Abstract: A new fermented product of soybean milk (designated “PS-B1”) was prepared by a four-step complex culture using 16 lactic acid bacteria of human intestinal origin. Because living lactic acid bacteria are completely removed by filtration of the fermented product, PS-B1 can be classified as a biogenic food. In the present study, we found that lipid accumulation was reduced significantly in 3T3-L1 adipocytes treated with PS-B1. Moreover, the production of IgE in response to ovalbumin was attenuated in rats fed with a diet containing PS-B1. Thus, PS-B1 represents one of the few biogenic food able to alter both lipid metabolism and ovalbumin-induced type I allergies, and is expected to find application in preventive medicine.

Keywords: Lactic Acid Bacteria, Soybean Milk, Biogenics, Lipid Metabolism, Ovalbumin-Induced Type I Allergy

1. Introduction

Probiotics are used around the world as foods for contributing to the enhancement of human health. In particular, probiotics fermented by lactic acid bacteria (LAB) have been used for centuries as traditional foods and medicines because of their multiple beneficial properties to human health and nutrition, including improvement of defecation, prevention of intestinal infection, and utilization of lactose [1-5]. Multiple reports indicate that oral administration of probiotics fermented by LAB provides moderate stimulation of the host’s immune system and controls serum cholesterol levels [6-9]. Therefore, priority has been placed on obtaining new functional species and strains of LAB in order to develop new probiotics.

On the other hand, much attention has been paid to “biogenics” as a new concept in functional food. Biogenics are defined as bacterial metabolic products without living microorganisms and are thought to harbor special properties able to directly affect the living body via intestinal organs. For example, two tripeptides (valyl-prolyl-proline and isoleucyl-prolyl-proline) isolated from Lactobacillus helveticus-fermented milk have been shown to control hypertension by inhibiting angiotensin-converting enzyme [10]. Recent advances in the development of detection methods (such as metabolomic and nutrigenomic analyses) have facilitated the elucidation of the relationships between the ingestion of biogenics and health-enhancing effects.

Although many soybean milks fermented by LAB have been prepared and consumed around the world, we are aware of few reports showing that foods classified as biogenics are effective in improving both lipid metabolism and food allergy. In the present study, we prepared a new biogenic food, PS-B1, by fermenting soybean milk via a four-step complex culture using 16 indigenous LAB of human intestinal origin (Figure 1). LAB used in the preparation of PS-B1 subsequently was removed from the product by filtration. In order to evaluate the positive effects of PS-B1 on lipid metabolism and food allergy, we firstly examined whether PS-B1 reduces lipid accumulation in mouse 3T3-L1 adipocytes. We secondly tested the effect of administering a diet containing PS-B1 to rats immunized with ovalbumin (OVA), demonstrating that PS-B1 attenuated the induction of type I allergy (the amount of serum anti-OVA immunoglobulin (Ig) E) in these animals.
2. Materials and Methods

2.1. Materials

The mouse 3T3-L1 preadipocytes were purchased from DS Pharma Biomedical Co., Ltd. (Osaka, Japan). The rat IgE ELISA kit used for detection of IgE was purchased from Shibayagi Co., Ltd. (Shibukawa, Gunma, Japan). All other reagents used in this study were high-quality analytical-grade materials.

2.2. Preparation of Soybean Milk Broths

We obtained organically grown soybeans from Akama Farm (Obihiroshihoro, Hokkaido, Japan). After the soybeans were treated at -2°C for 3 days and incubated at 10°C for 12 h, a sterilized soybean milk was made from the soybeans in Nishikawaya Tofuten (Kawaguchi, Saitama, Japan).

In this study, two types of soybean milk broth were used for preparation of PS-B1. Soybean milk broth 1 (50% soybean milk broth) was formulated in a mixture containing 6% skim milk, 0.1% glucose, and 0.1% yeast extract. Soybean milk broth 2 (80% soybean milk broth) was formulated in a mixture containing 2.4% skim milk, 0.5% glucose, and 0.4% yeast extract. Both broths were sterilized at 115°C for 15 min before use.

2.3. Preparation of PS-B1

PS-B1 was prepared from soybean milk broths by a four-step complex culture using 16 LAB, including organisms such as Lactobacilli, Bifidobacterium, and Enterococcus (Figure 1; Table 1). Individual LAB stored at -80°C were aerobically pre-cultivated at 34°C in de Man-Rogosa-Sharpe (MRS) broth (30 mL/broth) until the culture broth reached an optical density at 660 nm (OD660) of 1.3 (“primary cultures”).

As summarized in Table 1, the 16 LAB were divided into 9 groups consisting of 1-3 LAB each. Aliquots of MRS broth (1.5 mL/organism) from individual primary cultures were added to soybean milk broth 1 (60 mL) as shown in Table 1. These soybean milk broths inoculated with bacteria of the 9 groups were incubated aerobically at 34°C for 24 h as small-scale cultures (“secondary cultures”).

Next, aliquots of each of the 9 cultured broths (40 mL/group) obtained from secondary cultures were mixed in a sterile bottle. An aliquot (10 mL) of this mixture was added to 240 mL soybean milk broth 2 in a new sterile bottle, and the mixture was cultivated aerobically at 34°C for 24 h (“tertiary culture”).

Finally, the entire volume of the tertiary culture was added into a sterile tray filled with fresh soybean milk broth 2 (6.25 L) and then cultured aerobically under the following sequential conditions: 34°C for 27 h, 40°C for 48 h, and 65°C for 18 h. The fermented product of this “final culture” was homogenized at 6,000 rpm for 15 min using a homogenizer MEGATRON MT5000 (Central Scientific Commerce, Inc., Tokyo, Japan). The resulting suspension (6.5 kg) was transferred into a filtration-bag (Asahi Kasei Home Products Co., Ltd., Tokyo, Japan) and the filtrate was collected for 3 days. The resulting filtrate was filtered again using a 0.1-m hollow fiber membrane (Jyujiya Co., Ltd., Okayama, Japan); the sterile product, designated “PS-B1”, was lyophilized using a freeze dryer FDU-1200 (TOKYO RIKAKIKAI Co., Ltd., Tokyo, Japan). The lyophilized PS-B1 was employed in the following experiments.

2.4. Cell Culture and Oil Red O Staining

The mouse 3T3-L1 preadipocytes were seeded into
100-mm tissue culture dishes at a density of $1.0 \times 10^4$ cells/cm² in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% calf serum; the plates were then incubated at 37°C and 5% CO₂ in a humidified incubator. Two days after reaching confluence (experimental day 0), the differentiation of 3T3-L1 preadipocytes into adipocytes was induced by the addition of 0.5 mM 3-isobutyl-1-methyl xanthine, 0.25 mM dexamethasone, 1 µg/mL insulin, and 10% fetal bovine serum (FBS). On day 2, the induction medium was replaced with DMEM containing 1 µg/mL insulin and 10% FBS. On day 4, the medium was replaced with DMEM containing 10% FBS and PS-B1 (0-750 µg/mL); on day 6, the spent medium was replaced with fresh DMEM + FBS containing the same respective concentration of PS-B1.

On day 8, the cells were washed twice with phosphate-buffered saline at pH 7.4 (PBS), fixed by incubation with 10% formaldehyde in PBS for 20 min at room temperature, and then stained with 4 mL/plate of oil red O solution (1.8 mg/mL oil red O reagent in 60% isopropanol) for 20 min at room temperature. Excess stain was removed by washing twice with distilled water and oil red O internalized in lipid droplets was dissolved by the addition of 7 mL/plate of isopropanol. The absorbance of the dissolved dye was measured at 510 nm using a Tecan infinite M200 plate reader.

### 2.5. Ingestion of PS-B1

An animal experiment was conducted in accordance with the “Standards Relating to the Care and Management of Laboratory Animals and Relief of Pain” (Notice No. 88, Ministry of the Environment, Government of Japan). The experimental protocol in the animal experiments was approved by the Ethics Review Committee of Nagasaki International University (Approval No. 25). The schedule of the animal experiment is shown in Figure 2. Male Kud: Wistar rats at 4 weeks of age (Kyudo Co., Kumamoto, Japan) were individually housed in a room with controlled temperature, relative humidity, and light (23 ± 2°C, 60 ± 2% RH, and 7:00 to 19:00 h, respectively). The rats had free access to water and the CE-2 powder diet (CLEA Japan, Inc., Tokyo, Japan). After a week of acclimatization, the rats were randomly divided into four groups of five rats each. The control groups of rats were fed *ad libitum* with CE-2 powder diet (Groups I and II). For the experimental groups, the CE-2 powder diet was replaced (at 14 or 0 days after the acclimatization; Group III and IV, respectively) with a basal powder diet supplemented with 3% lyophilized PS-B1. General signs were observed daily, and the body weight of each rat was measured once a week. The amount of feed ingestion was estimated by weighing the leftovers each week.

**Figure 2.** Schedule of ingestion of PS-B1 and immunization with OVA in animal experiment. Male Kud: Wistar rats at 4 weeks of age were randomly divided into four groups (n = 5/group) after a week of acclimatization. The rats in Groups I and II were fed with CE-2 powder diet. In Groups III and IV, CE-2 supplemented with 3% lyophilized PS-B1 was given to rats from 14 or 0 days after the acclimatization, respectively. In rats of Groups II, III, and IV, immunization with OVA was performed 14, 21, and 35 days after the acclimatization; rats of Group I were immunized with vehicle on the same schedule. Blood samples were collected from all rats at one week after the final immunization.

### 2.6. Immunization with OVA

Immunization of rats was performed by using OVA as a soluble antigen. Briefly, a mixture of 1 mg/mL of OVA in PBS (100µL) and Inject Alum (Pierce Biotech., Inc., Rockford, Illinois, USA) was injected intraperitoneally into rats in Groups II, III, and IV at two weeks after acclimatization (Figure 2). Booster injections of the same amount of OVA in Inject Alum were administered 7 and 21 days after the initial injection. In Group I, animals were immunized on the same schedule but with equivalent volumes of a mixture of PBS (containing no antigen) and alum. Blood samples were collected from the immunized rats one week after the final injection. Following clotting and centrifugation, the resulting supernatant (antiserum) was stored at -20°C until used in the enzyme-linked immunosorbent assay (ELISA).
2.7. Detection of Anti-OVA IgE

To measure the amount of anti-OVA IgE in serum, the detection assay was performed using the rat IgE ELISA kit according to the instruction manual. The absorbance of the resulting reaction mixture in a 96-well microtiter plate was read at 414 nm on a Tecan infinite M200 plate reader.

2.8. Statistical Analysis

Each assay in detection of accumulated lipid and anti-OVA IgE was performed in triplicate; resulting data are presented as mean ± standard error. Statistical significance was evaluated using a two-tailed Student’s t-test; p values of < 0.05 were considered statistically significant.

3. Results and Discussion

3.1. Preparation of PS-B1

In this study, PS-B1 was prepared as a biogenic food from soybean milk by a four-step complex culture using 16 LAB (Figure 1). Primary cultures were performed using MRS broth for regenerating stored bacteria. In the secondary cultures, 9 individual groups of LAB were grown in separate aliquots of soybean milk broth 1 (Table 1). In the tertiary culture, aliquots of each of the secondary cultures were combined and then used as an inoculum for a bottle of soybean milk broth 2; the resulting mixture was grown as a small-scale culture. For the final culture, the tertiary culture was used to inoculate a large volume of soybean milk broth 2, yielding a large-scale culture. The final culture was subjected to filtration through a 0.3-µm filter, yielding a sterile product designated PS-B1. PS-B1 was expected to include not only soybean milk and components of killed microorganisms but also metabolites secreted by LAB. Multiple reports have indicated that the substances obtained from LAB fermentation provide health benefits [11-13]; we therefore assessed the health potential of the comprehensive mixture of substances included in PS-B1. Specifically, we used this novel fermented soybean milk product as biogenics in the following experiments.

3.2. Suppression Effect of PS-B1 on Lipid Accumulation

We evaluated the influence of PS-B1 on lipid accumulation in 3T3-L1 adipocytes, as assessed by oil red O staining. The differentiation of 3T3-L1 preadipocytes into adipocytes was induced by treatment with a mixture of 3-isooctyl-1-methyloxanthine, dexamethasone, and insulin; induced cells then were cultured for 4 days in DMEM medium containing PS-B1 at various concentrations. As shown in Figure 3, cells grown in medium containing PS-B1 accumulated significantly less oil red O compared to those grown in medium lacking the supplement; the effect of PS-B1 was nominally dose dependent. Specifically, when 3T3-L1 adipocytes were treated with PS-B1 at a concentration of 500 µg/mL, lipid accumulation was suppressed by approximately 16% compared to the control. Thus, supplementation of growth medium with PS-B1 yielded decreased lipid accumulation during in vitro growth of 3T3-L1 adipocytes.

In general, it is important to control lipid accumulation in adipocytes in order to maintain the levels of adipocytokines, such as adiponectin and leptin. Because food and food components contributing to the control of lipid accumulation are expected to be employed as anti-obesity foods, the elucidation of physiological mechanisms in their bioactivities are required. For example, Yi-Gan-San, which is a Chinese herbal medicine, has been shown to suppress lipid synthesis and fat accumulation in adipocytes through modulation of the activities of two transcription factors, sterol regulatory element-binding protein-1c (SREBP-1c) and forkhead box class O1 (FoxO1) [14]. The former transcription factor is the main regulator of the synthesis of fatty acids and cholesterol, and the latter is involved in adipocyte differentiation. In the present study, our results suggested that PS-B1 may include substances that suppress lipid synthesis or accelerate lipid degradation. In future work, we plan to investigate the molecular mechanism of action of PS-B1.

3.3. Influence of PS-B1 on Growth of Rats

We conducted an animal experiment examining the possibility of PS-B1 as biogenic therapy for the treatment of type I allergies, here modeled as the induction of an IgE response following immunization with OVA (Figure 2). In this animal experiment, the rats of Groups I and II were control animals, provided with ad lib access to the CE-2 powder diet lacking PS-B1. Rats of the latter group were immunized with OVA. The rats in Groups III and IV were provided with ad lib access to the CE-2 powder diet supplemented with 3% lyophilized PS-B1 for 4 and 6 weeks, respectively. The rats in
each of the groups exhibited similar changes in body weight; all animals grew well without marked differences in appearance (data not shown). No unscheduled mortality occurred in any of the groups during the study interval. These results indicated that the ingestion of PS-B1 at concentrations of up to 3% does not influence the growth of rats, confirming the safety of PS-B1. We note, however, that this result could be considered to contrast with the above observation (in Figure 3) that in vitro exposure of mouse adipocytes to PS-B1 resulted in significant decreases in lipid accumulation. PS-B1 may contribute to the normalization of lipid metabolism in obesity. Therefore, it will be critical to conduct further animal experiments testing PS-B1 supplementation in animals genetically predisposed to obesity and/or in animals maintained on high-fat or high-calorie diets. We hypothesize that PS-B1 effects on weight gain will be more readily detected in animal models of obesity.

3.4. Suppression Effect of PS-B1 on Production of Anti-OVA IgE

The amount of IgE response to OVA in serum obtained from rats in each group is shown in Figure 4. Comparison between Groups I and II showed that immunization with OVA yielded an approximately 9.8-fold increase in IgE levels, indicating that immunization was sufficient to stimulate IgE production in this model. Ingestion of PS-B1 yielded significant attenuation of IgE levels (Groups III and IV compared to Group II). Moreover, the amount of IgE in Group IV was significantly lower than that in Group III. Notably, PS-B1 was provided to rats in Group IV before immunization with OVA, while immunization and ingestion of PS-B1 were initiated on the same day for Group III. These results suggested that pre-ingestion of PS-B1 provides more effective attenuation of the activation of IgE production.

Most allergic diseases associated with immediate hypersensitivity are closely related to acceleration of IgE production. In general, the production of IgE results in type I allergy, owing to dominance of Th2-type immune responses. It is also known that the enhancement of Th1-type immunity suppresses Th2-type immune responses. In the present study, we investigated only the effect of PS-B1 on OVA-induced type I allergy. Further analysis will be needed to address the possible influence of PS-B1 on cytokines such as interferon (IFN)-γ, interleukin (IL)-4, IL-10, and IL-12; these factors may be involved in PS-B1’s effect on the production of anti-OVA IgE. For example, there are reports that the daily ingestion of Lactobacillus plantarum strain L-137 or KW3110 suppresses IgE production in vivo through IL-12 production, which induces the Th1-type immune response [15, 16]. In another example, a carbohydrate was shown to reduce the serum IgE level by suppression of IL-4 production and inactivation of Th2 response via the intestinal immune system [17]. Based on our results, we hypothesize that PS-B1 may increase Th1 cytokines and decrease Th2 cytokines.

PS-B1 is expected to include not only components of soybean milk and LAB-secreted metabolites, but also various LAB cell debris, including cell wall components (e.g., lipoteichoic acid and peptidoglycan) and genetic material (e.g., unmethylated CpG motifs from LAB DNA) [18-21]. Therefore, it is possible that the effects of PS-B1 are mediated by the direct influence of these substances on immune cells. On the other hand, oral L-92 administration has been reported to regulate both Th1 and Th2 cytokine responses, to suppress serum anti-OVA IgE, and to induce transforming growth factor (TGF)-β production in Peyer's patch cells [22]. In vivo, PS-B1 may activate the intestinal immune system represented by Peyer's patch cells and/or alter intestinal microbiota.

We have additional data supporting the effect of PS-B1 on the improvement of OVA-induced type I allergy. In a metabolomic analysis (currently in progress) of LAB-metabolized soybean milk, we have observed elevated levels of cepharanthine (data not shown), an alkaloid known to indicate anti-inflammatory, anti-oxidative, anti-allergic, and immunomodulatory activities [23, 24]. Macrophages have been shown to produce Th2 cytokines when in an oxidative environment and to produce Th1 cytokines when in a reductive environment [25, 26]; thus the presence of antioxidants in PS-B1 may contribute to mucosal immunity.

4. Conclusion

In this study, we prepared PS-B1, a biogenic fermented product of soybean milk that is generated by a four-step complex culture using 16 indigenous LAB. Subsequent analysis demonstrated that PS-B1 improves lipid metabolism in vitro and attenuates OVA-induced type I allergy in vivo. The precise molecular mechanism(s) responsible for the effects of PS-B1 on the lipid accumulation and the IgE production remain undefined. Since we expect that PS-B1 is a candidate for daily use as a biogenic food suitable for preventive medicine, further investigations will be needed to
address these and further issues.

Acknowledgments

The authors express their sincere thanks to Dr. Fukasawa (Nagasaki International University, Sasebo, Nagasaki, Japan) for providing experimental information on ELISA. This work was supported by a grant-in-aid for scientific research from Ministry of Education, Culture, Sports, Science, and Technology of Japan (Grant No. 24700854).

References


